QXO, Inc. (QXO)
Live price chart, market sentiment, and community perspectives for QXO, Inc. (NYSE: QXO).
Live price chart, market sentiment, and community perspectives for QXO, Inc. (NYSE: QXO).
On our desk, the debate centers squarely on Brad Jacobs' track record versus the immediate valuation reality. QXO has executed a massive roll-up in just 15 months—acquiring Beacon Roofing, Kodiak Partners, and closing the $17 billion TopBuild deal. While this builds an unmatched $18 billion revenue platform, the market is severely punishing the stock with a 27% year-to-date decline. Investors are grappling with whether the long-term blueprint for $4 billion in organic EBITDA by 2030 justifies the current dilution, rising leverage to 2.85x, and a macro environment plagued by a soft housing cycle and higher interest rates. Until integration stabilizes margins, sentiment remains cautious.
Looking closely at the Q2 2026 reporting and subsequent TopBuild integration, the fundamental risk has shifted cleanly from valuation multiples to direct per-share earnings drag. Despite reporting $3.25 billion in second-quarter sales—up sharply from $1.91 billion year-over-year—the company posted a basic and diluted loss per common share of $(0.14), with adjusted diluted EPS at $0.08. Furthermore, preferred overhang and expanded share counts have heavily diluted common shareholders. With Oppenheimer and other desks highlighting ongoing near-term headwinds, we see little room for multiple expansion until clear margin inflections materialize.
From a quantitative and structural analysis perspective, assessing QXO requires parsing the noise of top-line revenue inflation caused by constant MandA. Analysts modeling the business must separate organic performance from legacy integrations like Kodiak and Beacon. The strategic bet on cross-selling, procurement synergies, and technology rollouts across 1,150 locations is sound in theory, but execution risk is exceptionally high. When evaluating entry points, look past the headline EV/EBITDA of roughly 13.9x and focus strictly on cash flow generation, debt service capacity on the $9 billion total debt stack, and whether institutional backing from Apollo and Temasek provides enough runway for the multi-year thesis to play out.
Explore plasma cleansing, somatic organ swaps, and BCI.